Alto Neuroscience, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-63.2M | $-61.4M | $-36.3M |
| Depreciation & Amortization | — | $502.0K | $373.0K |
| Depreciation | $661.0K | $502.0K | — |
| Amortization | — | — | — |
| Stock-Based Compensation | $8.1M | $7.6M | $2.9M |
| Net Cash from Operating Activities | $-51.8M | $-47.4M | $-33.4M |
| Investing Activities | |||
| Capital Expenditures | $24.0K | $2.1M | $470.0K |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-24.0K | $-2.1M | $-470.0K |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $60.1M | $135.7M | $68.1M |
| Net Change in Cash | $8.3M | $86.2M | $34.2M |
| Free Cash Flow | $-51.8M | $-49.5M | $-33.9M |